Retinal vein occlusions

Developments in Ophthalmology

Volumn 46, Issue , 2010, Pages 54-72

  Buehl, Wolf ^a   Sacu, Stefan ^a   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; VASCULOTROPIN A;

ARTICLE; BLOOD FLOW; DRUG ANTAGONISM; EYE SURGERY; FIBRINOLYTIC THERAPY; HEMATOLOGIC DISEASE; HUMAN; ISCHEMIA; LASER COAGULATION; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; RECURRENT DISEASE; RETINA BLOOD VESSEL; RETINA DISEASE; RETINA VEIN OCCLUSION; RISK FACTOR; VASCULITIS;

ADRENAL CORTEX HORMONES; HEMATOLOGIC DISEASES; HUMANS; ISCHEMIA; LASER COAGULATION; NEOVASCULARIZATION, PATHOLOGIC; OPHTHALMOLOGIC SURGICAL PROCEDURES; PRIMARY PREVENTION; RECURRENCE; REGIONAL BLOOD FLOW; RETINAL DISEASES; RETINAL VEIN OCCLUSION; RETINAL VESSELS; RISK FACTORS; THROMBOLYTIC THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULITIS;

EID: 84925958662     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320009     Document Type: Article

References (100)

1. Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-282.
2. Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-491.
3. Parodi MB, Bandello F: Branch retinal vein occlusion: classification and treatment. Ophthalmologica 2009;223:298-305.
4. Klein R, Klein BE, Moss SE, Meuer SM: The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000;98:133-141.
5. Noma H, Funatsu H, Yamasaki M, et al: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-261.
6. Kumar B, Yu DY, Morgan WH, Barry CJ, Constable IJ, McAllister IL: The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 1998;105:424-427.
7. Mitchell P, Smith W, Chang A: Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 1996;114:1243-1247.
8. Cugati S, Wang JJ, Rochtchina E, Mitchell P: Tenyear incidence of retinal vein occlusion in an older population. The Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726-732.
9. David R, Zangwill L, Badarna M, Yassur Y: Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1998;197:69-74.
10. Bearelly S, Fekrat S: Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin 2004;44:85-102.
11. Weinberg D, Dodwell DG, Fern SA: Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990;109:298-302.
12. Scott IU: Vitreoretinal surgery for complications of branch retinal vein occlusion. Curr Opin Ophthalmol 2002;13:161-166.
13. Feist RM, Ticho BH, Shapiro MJ, Farber M: Branch retinal vein occlusion and quadratic variation in arteriovenous crossings. Am J Ophthalmol 1992;113:664-668.
14. Christoffersen NL, Larsen M: Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999;106:2054-2062.
15. Janssen MC, den Heijer M, Cruysberg JR, Wollersheim H, Bredie SJ: Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005;93:1021-1026.
16. Rehak J, Rehak M: Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-131.
17. Ingerslev J: Thrombophilia: a feature of importance in retinal vein thrombosis? Acta Ophthalmol Scand 1999;77:619-621.
18. Tekeli O, Gürsel E, Buyurgan H: Protein C, protein S and antithrombin III deficiencies in retinal vein occlusion. Acta Ophthalmol Scand 1999;77:628-630.
19. Tost F: Venous branch occlusion due to APC resistance. Ophthalmologe 1999;96:777-780.
20. Hayreh SS: Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 2005;24:493-519.
21. Barbazetto IA, Schmidt-Erfurth UM: Evaluation of functional defects in branch retinal vein occlusion before and after laser treatment with scanning laser perimetry. Ophthalmology 2000;107:1089-1098.
22. Chen HC, Wiek J, Gupta A, et al: Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998;82:162-167.
23. Hansen LL, Wiek J, Arntz R: Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion (in German). Fortschr Ophthalmol 1988;85:514-516.
24. Poupard P, Eledjam JJ, Dupeyron G, et al: Role of acute normovolemic hemodilution in treating retinal venous occlusions (in French). Ann Fr Anesth Reanim 1986;5:229-233.
25. Shahid H, Hossain P, Amoaku WM: The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006;90:627-639.
26. Glacet-Bernard A, Coscas G, Chabanel A, et al: A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994;118:421-429.
27. De Sanctis MT, Cesarone MR, Belcaro G, et al: Treatment of retinal vein thrombosis with pentoxifylline: a controlled, randomized trial. Angiology 2002;53(suppl 1):35-38.
28. Sharma A, D'Amico DJ: Medical and surgical management of central retinal vein occlusion. Int Ophthalmol Clin 2004;44:1-16.
29. Hattenbach LO, Friedrich Arndt C, Lerche R, et al: Retinal vein occlusion and low-dose fibrinolytic therapy: a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina 2009;29:932-940.
30. Steigerwalt RD Jr, Cesarone MR, Belcaro G, et al: Retinal and orbital venous occlusions treated with enoxaparin. J Ocul Pharmacol Ther 2008;24:421-426.
31. Lahey JM, Fong DS, Kearney J: Intravitreal tissue plasminogen activator for acute central retinal vein occlusion. Ophthalmic Surg Lasers 1999;30;427-434.
32. Weiss JN, Bynoe LA: Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology 2001;108:2249-2257.
33. Houtsmuller AJ, Vermeulen JA, Klompe M, et al: The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984;15:219-229.
34. Parodi MB, Saviano S, Bergamini L, Ravalico G: Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc Ophthalmol 1999;97:427-431.
35. Parodi MB, Saviano S, Ravalico G: Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1999;237:1024-1027.
36. Parodi MB, DI Stefano G, Ravalico G: Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 2008;28:97-102.
37. McIntosh RL, Mohamed Q, Saw SM, Wong TY: Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:835-846.
38. Branch Vein Occlusion Study Group: Argon laser scatter photocoagulation for prevention of neovascularization and hemorrhage in branch vein occlusion. Arch Ophthalmol 1986;104:34-41.
39. McAllister IL, Douglas JP, Constable IJ, et al: Laserinduced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors. Am J Ophthalmol 1998;126:219-229.
40. Quiroz-Mercado H, Sanchez-Buenfil E, Guerrero-Naranjo JL, et al: Successful erbium: YAG laserinduced chorioretinal venous anastomosis for the management of ischemic central retinal vein occlusion. A report of two cases. Graefes Arch Clin Exp Ophthalmol 2001;239:872-875.
41. Osterloh MD, Charles S: Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol 1988, 106:1469-1471.
42. Chung EJ, Freeman WR, Koh HJ: Visual acuity and multifocal electroretinographic changes after arteriovenous crossing sheathotomy for macular edema associated with branch retinal vein occlusion. Retina 2008, 28:220-225.
43. Chung EJ, Lee H, Koh HJ: Arteriovenous crossing sheathotomy versus intravitreal triamcinolone acetonide injection for treatment of macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:967-974.
44. Garcia-Arumi J, Martinez-Castillo V, Boixadera A, Blasco H, Corcostegui B: Management of macular oedema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator. Retina 2004;24:530-540.
45. Yamamoto S, Saito W, Yagi F, Takeuchi S, Sato E, Mizunoya S: Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2004;138:907-914.
46. Kumagai K, Furukawa M, Ogino N, Uemura A, Larson E: Long-term outcomes of vitrectomy with or without arteriovenous sheathotomy in branch retinal vein occlusion. Retina 2007;27:49-54.
47. Avci R, Inan U, Kaderli B: Evaluation of arteriovenous crossing sheathotomy for decompression of branch retinal vein occlusion. Eye 2008;22:120-127.
48. Horio N, Horiguchi M: Effect of arteriovenous sheathotomy on retinal blood flow and macular edema in patients with branch retinal vein occlusion. Am J Ophthalmol 2005;139:739-740.
49. Mason J, Feist R, White M Jr, Swanner J, McGwin G Jr, Emond T: Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology 2004;111:540-545.
50. Han D P, Bennett SR, Williams DF, Dev S: Arteriovenous crossing dissection without separation of the retina vessels for treatment of branch retinal vein occlusion. Retina 2003;23:145-151.
51. Uemura A, Yamamoto S, Sato E, Sugawara T, Mitamura Y, Mizunoya S: Vitrectomy alone versus vitrectomy with simultaneous intravitreal injection of triamcinolone for macular edema associated with branch retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2009;40:6-12.
52. Ma J, Yao K, Zhang Z, Tang X: 25-Gauge vitrectomy and triamcinolone acetonide-assisted internal limiting membrane peeling for chronic cystoid macular edema associated with branch retinal vein occlusion. Retina 2008;28:947-956.
53. Mandelcorn MS, Nrusimhadevara RK: Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina 2004;24:348-355.
54. Mandelcorn MS, Mandelcorn E, Guan K, Adatia FA: Surgical macular decompression for macular edema in retinal vein occlusion. Can J Ophthalmol 2007;42:116-122.
55. McAllister IL, Vijayasekaran S, Chen SD, Yu DY: Effect of triamcinolone acetonide on vascular endothelial growth factor and occludin levels in branch retinal vein occlusion. Am J Ophthalmol 2009;147:838-846.
56. SCORE Study Research Group: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: The Standard Care vs. Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 6. Arch Ophthalmol 2009;127:1115-1128.
57. Avitabile T, Longo A, Reibaldi A: Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. Am J Ophthalmol 2005;140:695-702.
58. Ozkiris A, Evereklioglu C, Erkilic K, Dogan H: Intravitreal triamcinolone acetonide for treatment of persistent macular edema in branch retinal vein occlusion. Eye 2007;20:13-17.
59. Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF: Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71.
60. Cekic O, Chang S, Tseng JJ, et al: Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-855.
61. Lee H, Shah GK: Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005;25:551-555.
62. Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL: Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2005;36:30-36.
63. Chen SD, Sundaram V, Lochhead J, Patel CK: Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876-883.
64. Karacorlu M, Ozdemir H, Karacorlu SA: Resolution of serous macular detachment after intravitreal triamcinolone acetonide treatment of patients with branch retinal vein occlusion. Retina 2005;25:856-860.
65. Roth DB, Cukras C, Radhakrishnan R, et al: Intravitreal triamcinolone acetonide injections in the treatment of retinal vein occlusions. Ophthalmic Surg Lasers Imaging 2008;39:446-454.
66. Cakir M, Dogan M, Bayraktar Z, et al: Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28:465-472.
67. Patel PJ, Zaheer I, Karia N: Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye 2008;22:60-64.
68. Ozdek S, Deren YT, Gurelik G, Hasanreisoglu B: Posterior subtenon triamcinolone, intravitreal triamcinolone and grid laser photocoagulation for the treatment of macular edema in branch retinal vein occlusion. Ophthalmic Res 2008;40:26-31.
69. Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H: Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1671-1676.
70. Parodi MB, Iacono P, Ravalico G: Intravitreal triamcinolone acetonide combined with subthreshold grid laser treatment for macular oedema in branch retinal vein occlusion: a pilot study. Br J Ophthalmol 2008;92:1046-1050.
71. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA: Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
72. Jonas JB, Degenring RF, Kreissig I, Akkoyun I: Safety of intravitreal high-dose reinjections of triamcinolone acetonide. Am J Ophthalmol 2004;138:1054-1055.
73. Scott IU, Flynn HW Jr: Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27:10-12.
74. Kuppermann BD, Blumenkranz MS, Haller JA, et al: Dexamethasone DDS Phase II Study Group: Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;125:309-317.
75. Kawaji T, Takano A, Inomata Y, et al: Trans-Tenon's retrobulbar triamcinolone acetonide injection for macular oedema related to branch retinal vein occlusion. Br J Ophthalmol 2008;92:81-83.
76. Kawaji T, Hirata A, Awai N, et al: Trans-Tenon retrobulbar triamcinolone injection for macular edema associated with branch retinal vein occlusion remaining after vitrectomy. Am J Ophthalmol 2005;140:540-542.
77. Hayashi K, Hayashi H: Intravitreal versus retrobulbar injections of triamcinolone for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2005;139:972-982.
78. Wakabayashi T, Okada AA, Morimura Y, et al: Trans-Tenon retrobulbar triamcinolone infusion for chronic macular edema in central and branch retinal vein occlusion. Retina 2004;24:964-967.
79. Prager F, Michels S, Kriechbaum K, et al: Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-456.
80. Badalà F: The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008;19:234-238.
81. Gregori NZ, Rattan GH, Rosenfeld PJ, et al: Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion. Retina 2009;29:913-925.
82. Ahmadi AA, Chuo JY, Banashkevich A, Ma PE, Maberley DA: The effects of intravitreal bevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol 2009;44:154-159.
83. Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P: One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27-33.
84. Abegg M, Tappeiner C, Wolf-Schnurrbusch U, Barthelmes D, Wolf S, Fleischhauer J: Treatment of branch retinal vein occlusion induced macular edema with bevacizumab. BMC Ophthalmol 2008;29:8-18.
85. Chung EJ, Hong YT, Lee SC, Kwon O W, Koh HJ: Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241-1247.
86. Kriechbaum K, Michels S, Prager F, et al: Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-522.
87. Kreutzer TC, Alge CS, Wolf AH, et al: Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-355.
88. Wu L, Arevalo JF, Roca JA, et al: Pan-American Collaborative Retina Study Group (PACORES): Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212-219.
89. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419-425.
90. Spandau U, Wickenhauser A, Rensch F, Jonas J: Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 2007;85:118-119.
91. Stahl A, Struebin I, Hansen LL, Agostini HT, Feltgen N: Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol 2010;20:180-185.
92. Guthoff R, Meigen T, Hennemann K, Schrader W: Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion - a matched-pairs analysis. Ophthalmologica 2010;224:126-132.
93. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, Murray TG: Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. Retina 2008;28:1325-1337.
94. Wu WC, Cheng KC, Wu HJ: Intravitreal triamcinolone acetonide vs. bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye 2009;23:2215-2222.
95. Funk M, Kriechbaum K, Prager F, et al: Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
96. Park SP, Ahn JK: Changes of aqueous vascular endothelial growth factor and pigment epitheliumderived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion. Clin Exp Ophthalmol 2009;37:490-495.
97. Campochiaro PA, Hafiz G, Shah SM, et al: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-799.
98. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056.
99. Yazdani S, Hendi K, Pakravan M: Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437-439.
100. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU: Tübingen Bevacizumab Study Group: Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006;142:158-160.